Joining us from their lab space in Raleigh, Executive Director Josh Sommer and CSO Dan Freed introduce us to chordoma and describe the...

Hatteras Venture Partners' Clay Thorp describes the growth of North Carolina's biotech industry during his firm's 20+ years of...

Chris McCarthy describes how investors are anticipating upcoming binary events and how they have been talking about broader market issues.

Roberto Bellini introduces us to his new investment firm and looks back on lessons learned from selling BELLUS to GSK.

Noël Brown shares his thoughts on the IPO market and its pipeline, following-on offerings, and takaways from the RBC Capital Markets...

Brian Abrahams previews the conference, shares his take on biotech, and offers some themes to watch throughout the remainder of the year.

Emily Walsh Martin covers regulatory comments from FDA's Peter Marks, scientific updates on prime and base editing, and more.

TJ Cradick gives us a preview of which abstracts and technologies to watch this year, including the latest in gene editing methods and...

An early adopter and researcher of AI, Noam Auslander shares her opinion of the benefits of AI but also guardrails that should be...

He explains how machine learning has allowed bit.bio to model which transcription factor combinations are needed to create a desired cell...

CIC Partner Michael Anstey describes the firm's history and investment approach, lists some current investments, and offers advice for...

Kathryn Chapman has held many roles in town and is an expert on everything Cambridge's life sciences ecosystem has to offer.

Executive director Cathy Tralau-Stewart describes how Milner fosters partnerships.

He will be presenting final data from a 21 patient NHL cohort at the 2024 ASCO Annual Meeting in June.

OSE Partner Claire Brown describes the important role that OSE plays in the helping to turn ideas into companies at Oxford.

Alek Safarian shares his opinions on the current funding environment for biotech, and introduces us to his firm and its investment...

He says that intrathecal administration as well as taking a dual target approach are key factors that have led to improvements over...

He describes how Cloverleaf believes it is different from other tRNA companies and how it has already at the earliest stages benefitted...

McKinsey Boston life science specialists give their take on the goals of the summit and the current state of the sector.

He talks about GV's history in healthcare and lists some investments made in the nearly five years he has been there.